2228.HK XtalPi (HKSE) down 2.40% intraday 05 Feb 2026: 23.90% model upside

The 2228.HK stock opened lower and trades at HK$11.38, down 2.40% intraday on 05 Feb 2026 on the HKSE in Hong Kong. Volume is elevated at 48,589,589.00 shares against a 50-day average of 76,674,218.00, signalling active trading in this AI drug-discovery name. XtalPi Holdings Ltd (2228.HK) mixes AI platforms and lab automation across China, the US and Japan and faces near-term news flow ahead of earnings on 2026-03-27. We review valuation, technicals, Meyka AI forecasts, and the key catalysts for AI-sector investors focused on 2228.HK stock.

Intraday price action and volume: 2228.HK stock

XtalPi trades at HK$11.38, with a day low of HK$11.11 and a day high of HK$11.58, down from a previous close of HK$11.66. The intraday decline of 2.40% follows heavy turnover of 48,589,589.00 shares, below the average volume of 76,674,218.00, suggesting profit-taking after recent gains.

Valuation and fundamentals snapshot: 2228.HK stock

The financial picture shows EPS HK$1.04 and a trailing PE of 10.94, with market capitalization near HK$48,972,370,640.00. Price-to-sales at 63.88 and price-to-book at 5.44 flag a premium valuation versus healthcare peers in Hong Kong.

Balance sheet and cash flow context: 2228.HK stock

XtalPi reports cash per share HK$0.92 and a current ratio of 9.69, indicating strong short-term liquidity. Free cash flow is negative at -0.13 per share (TTM), and net income per share is -0.05, so operating cash burn and R&D intensity remain investment risks for AI-focused buyers.

AI product strategy and revenue growth: 2228.HK stock

XtalPi sells AI-enabled drug discovery tools such as XMolGen, XtalFold and Xtalgazer across multiple regions. Revenue rose to CNY266.43 million in 2024, a 52.75% increase year-over-year, showing commercial traction for AI-enabled services in drug research.

Meyka AI grade and technical signals: 2228.HK stock

Meyka AI rates 2228.HK with a score out of 100: the platform gives a 59.16 / 100, Grade C+ (HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts and analyst consensus. Technically, short-term momentum is strong with RSI 76.82 (overbought), MACD 0.39 and Bollinger upper band at HK$11.80, indicating near-term upside pressure but stretched positioning.

Risks, catalysts and trading considerations: 2228.HK stock

Key catalysts include the upcoming earnings release on 2026-03-27, new commercial contracts, and drug-discovery milestones. Major risks are rich valuation ratios, continued negative operating cash flow, and regulatory or clinical setbacks. Recent company-level sentiment shows a dated third-party rating of C- (Strong Sell) on 2026-02-04, underscoring mixed views among data providers.

Final Thoughts

2228.HK stock sits at HK$11.38 on 05 Feb 2026 with mixed signals for AI investors. Fundamentals show fast revenue growth—CNY266.43 million in 2024—but negative net income and free cash flow per share highlight execution risk. Technically, momentum is strong (RSI 76.82), yet positioning is stretched. Meyka AI’s forecast model projects a monthly target of HK$14.10, an implied upside of 23.90% versus the current price, and a quarterly view of HK$13.43. These model-based targets offer a short-term framework for traders but are not guarantees. For longer-term AI-stock investors, monitor the 2026-03-27 earnings, R&D-to-revenue trends (R&D share ~63.06% TTM), and any commercial partnership updates. We note XtalPi trades on the HKSE in Hong Kong and carries a premium PS and PB relative to sector medians. Use position sizing that accounts for high volatility and the difference between Meyka AI’s C+ HOLD grade and other third-party signals. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.